Join us for a morning where biological insight meets therapeutic ambition, and the path from concept to clinic comes into sharp focus. Medicon Valley Alliance and Syngene International would like to welcome you to a Good Morning Meeting 21th of January 2026.
Engage with leaders shaping tomorrow’s treatments, and gain perspectives that strengthen scientific collaboration and innovation.
Date: Wednesday, 21 January 2026
Time: 8:30 – 11:00
Venue: Medicon Valley Alliance, Arne Jacobsens Allé 15, 2300 Copenhagen S, Denmark – Hub 2
Program
| 8:30 | Networking, registration and light breakfast |
| 9:00 | Welcome and introduction to Medicon Valley Alliance David Munis Zepernick, Director, Member Engagement & Communication, Medicon Valley Alliance |
| 9:05 | Welcome and introduction to Syngene Mattias Nyström, Senior Director Business Development, Northern Europe, Syngene International Ltd. |
| 9:15 | Making the Untreatable Treatable: Translating Biology into Medicine, Focus and build excellence in the translation of biological insight and concept into innovative medical treatment and thereby improve the likelihood to treat untreatable disorder Allan Wehnert, CEO & Founder, Orocidin A/S |
| 9:45 | Follow the Molecule: from Discovery to Commercialization Stephane Lefevre, Director Business development, Peptides and Oligonucleotides, Syngene International Ltd. |
| 10:00 | Networking |
| 11:00 | End of Good Morning Meeting |
Speakers
| Organized by | In collaboration with |
![]() |
![]() |





